

SPIL/CS/SE/2023-2024/14

Date:02.08.2023

To,
Sr. General Manager
Listing Operation
BSE Limited,
P.J. Towers Dalal Street,
Mumbai – 400 001

BSE Scrip Code: 543828
BSE Trading Symbol: SUDARSHAN
ISIN: INE00TV01015

Subject: Intimation for Acquisition of the shares of the Company (Wholly Owned Subsidiary) & Outcome of the Meeting of Board of Directors of the company held on August 02, 2023.

Reference: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)-

Dear Sir/Madam,

With reference to the captioned subject matter, this is to inform you that a Meeting of Board of Directors of the company was held on 02nd August, 2023 at the Registered Office of the company at 2.00 PM

The Board of Directors at its Meeting held on 02nd August, 2023 had discussed and approved the following interalia along with other items:

1. With reference to the captioned subject matter and pursuant to Reg. 30 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we would like to inform your kind office that, Sudarshan Pharma Industries Limited (the Company) has entered in to an Agreement for Subscription of shares of Ratna Lifesciences Private Limited equivalent to 100% of the shareholding of the Company as wholly owned subsidiary Company, as on date 02nd August,2023, representing 100% holding in Ratna Lifesciences Private Limited.

“Ratna Lifescience” will fall under the category of a Wholly-owned Subsidiary Company (CIN: U74999PN2017PTC168995) and is registered under the Companies Act, 2013 with the Registrar of Companies, Pune.

The details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated 9th September 2015, are given in **Annexure-A**.

2. To incorporate another Subsidiary Company- the in principal approval is being accorded and further process is subject to approval by respective Registrar of Companies (“Roc Office”), the registered office of the company will be in the state of Gujarat, under RoC office Ahemadabad, as per deliberation held in today’s meeting, further it was unanimously decided that this agenda shall be taken and resolved upon at a future date once requisite approvals are received from RoC Office.

The meeting of board of directors concluded at 7:15 PM

Kindly take the same on record and acknowledge receipt.

Thanks & Regards,

Yours faithfully,

For Sudarshan Pharma Industries Limited

Mr. Hemal Mehta

Chairman & Managing Director

Annexure-A.

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 are given below:

SL NO	Details to be Provided	Information
1	Name of the target entity, details in brief such as size, etc.	<p>Name: Ratna Lifesciences Private Limited</p> <p>Equity Share Capital: INR 1,00,000/- The Whole Capital is divided 10,000 Shares having INR 10 per value.</p> <p>Turnover:2,17,220/-</p>
2	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of the interest and details thereof and whether the same is done at 'arm's length'	NO
3	Industry to which the entity being acquired belongs.	Business of buy, sale, manufacture, import, export, distribute, extract, implement, test, consult, promote, develop, improvise, innovate, assemble, wholesale and/or retail trade in all kinds and varieties of healthcare products, Ayurveda and dietary supplement products, medicinal preparations, vaccines, chemicals, chemical products, materials, pharmaceuticals, antibiotics, drugs, medicines, biologicals, nutraceuticals in India and any part of the world
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The Company is has a similar line of business with readymade technology and expertise in API and Oncology Products, further this acquisition is for expansion and enhancements of verticals of business

5	Brief details of governmental or any regulatory approvals "required for the acquisition	NA
6	Indicative time period for completion of the acquisition	Indicative Date of completion of acquisition: 30 th August,2023
7	Nature of Consideration whether Cash consideration or share swap and details of the same	To be subscribed in cash.
8	Cost of Acquisition or the price at which the shares are acquired.	INR. 550.00 Lakhs only (Rs. Five hundred Fifty Lakhs only - the "Purchase Price")
9	Percentage of shareholding control acquired and /or number of shares acquired	100% of the paid-up Share Capital of the subsidiary is held by the Sudarshan Pharma Industries Limited
10	Brief background about the entity acquired in terms of products/ line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p><u>Brief background:</u></p> <p>M/s Ratna Lifesciences Private limited was established on 20th February 2017. The company was situated in serene environment and is perfect for the intermediate and active pharmaceutical products. The company was established with the aim to develop and manufacture oncology category intermediate products. The annual capacity of the product at the time of establishment was 2 metric tonnes per annum. The expandable capacity is 15 metric tonnes per annum.</p> <p>M/s. Ratna Life science strongly believe in the continuous process improvement, development of new molecules and capacity expansion.</p> <p>M/s. Ratna Lifesciences Private Limited is also in the process to acquire adjacent MIDC land to increase the plot area. This will enable Ratna Life science to multiply the plant capacity and increase the annual turnover approximately by 10 times than the existing capacity and annual turnover.</p> <p><u>Date of Incorporation:</u> 20th February, 2017</p> <p><u>History of last 3 years' turnover:</u> <u>Financial Year</u></p>

		<p>2021-2022 - 5023.13 (Amount in Thousand)</p> <p>2020-2021 - 8121.42(Amount in Thousand)</p> <p>2019-2020- 4915.17(Amount in Thousand)</p> <p><u>Country in which the acquired entity has presence: India</u></p>
--	--	---